Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Without Borders
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Practice Current
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Without Borders
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Practice Current
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

April 2015; 2 (2) Clinical/Scientific NotesOpen Access

Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse

Inês Brás Marques, Stuart Flanagan, Heather Noble, Gavin Giovannoni, Monica Marta
First published February 12, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000074
Inês Brás Marques
From the Blizard Institute (I.B.M., G.G., M.M.), Queen Mary University London; and Barts Health NHS Trust (S.F., H.N.), London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Flanagan
From the Blizard Institute (I.B.M., G.G., M.M.), Queen Mary University London; and Barts Health NHS Trust (S.F., H.N.), London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Noble
From the Blizard Institute (I.B.M., G.G., M.M.), Queen Mary University London; and Barts Health NHS Trust (S.F., H.N.), London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gavin Giovannoni
From the Blizard Institute (I.B.M., G.G., M.M.), Queen Mary University London; and Barts Health NHS Trust (S.F., H.N.), London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Marta
From the Blizard Institute (I.B.M., G.G., M.M.), Queen Mary University London; and Barts Health NHS Trust (S.F., H.N.), London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse
Inês Brás Marques, Stuart Flanagan, Heather Noble, Gavin Giovannoni, Monica Marta
Neurol Neuroimmunol Neuroinflamm Apr 2015, 2 (2) e74; DOI: 10.1212/NXI.0000000000000074

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
506

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Case report.

A 37-year-old woman was admitted with seizures, confusion, and fever following weeks of apathy and self-neglect. HIV-1 infection and cerebral toxoplasmosis were diagnosed 4 months before, with good clinical and radiologic response to sulfadiazine and pyrimethamine after 1 month1 (figure, A). After discharge she had poor adherence to antitoxoplasmosis and antiretroviral drugs.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Brain MRI of the patient throughout the disease course

(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis treatment (b). (B) Brain MRI at admission showing increase in lesion number and contrast uptake. (C) Brain MRI showing radiologic response to toxoplasmosis treatment. (D) Brain MRI after progressive clinical deterioration showing increase in lesion number and multiple new enhancing vessels in the perforator and peripheral distribution of middle cerebral artery territories. (E) Brain MRI after 2 months of foscarnet treatment. Despite significant clinical improvement, radiologic lesions persist.

At this admission, examination revealed slow verbal and motor responses, disorientation, and pyrexia (38°C). Hemoglobin was 5.9 g/dL, CD4 = 4 cells/μL (1%), and HIV viral load was 114.294 copies/mL. Serologies were reactive for Toxoplasma and negative for Cryptococcus, hepatitis B and C, and syphilis. Brain MRI revealed more gadolinium-enhancing lesions (figure, B). Toxoplasmosis treatment and truvada/darunavir/ritonavir were restarted, with clinical and radiologic improvement of enhancement pattern after 6 weeks (figure, C).

Two weeks later, clinical worsening ensued, with fluctuating consciousness, apathy, aphasia, and food and medication refusal. MRI showed significant increase in T2/fluid-attenuated inversion recovery lesion number and extension and multiple new hemorrhagic and enhancing lesions following arterial territories (figure, D). CSF analysis showed 8 white cells/mm3, protein 1,330 mg/dL, and positive varicella-zoster virus (VZV) DNA (negative cryptococcal antigen, HIV, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, and adenovirus PCR, antineuronal antibodies). Acyclovir (10 mg/kg, tid) was added.

Deterioration continued, with no eye or verbal response to stimuli, food and medication refusal, and tetraparesis with hyperreflexia and bilateral extensor plantar response. EEG excluded status epilepticus. CSF showed 1,350 erythrocytes/mm3, protein 2,400 mg/dL, no lymphocytes, and lower VZV DNA copies.

VZV hemorrhagic encephalitis with vasculopathy was assumed, so foscarnet (60 mg/kg/day) and IV methylprednisolone (3 g over 3 days) were added. Rapid improvement ensued, with the patient being alert with spontaneous eye opening and directing gaze to stimuli after 2 days and showing intentional movements later. Throughout, her attention fluctuated and she refused to engage. Despite considerable clinical improvement, MRI performed 2 months later still demonstrated widespread cerebral lesions (figure, E).

Discussion.

Encephalitis etiology frequently remains unknown.2,3 In immunosuppressed patients, CNS infections are among the most common complications, but clinical, radiologic, and laboratory features are similar in CNS infections, neoplasms, and HIV encephalopathy. Concurrent CNS pathologies must be considered when patients do not respond to treatment or present with rebound worsening, after excluding treatment nonadherence, drug resistances, misdiagnosis, and immune reconstitution inflammatory syndrome (IRIS). Toxoplasmosis-IRIS is rare, and new perivascular/vascular gadolinium-enhancing lesions extending through perforator territories of middle cerebral arteries with punctate hemorrhagic signal with restricted diffusion-weighted signal areas and CSF VZV DNA were more suggestive of VZV vasculopathy in the case reported.

VZV is estimated to cause 5%–8% of adult encephalitis cases.3 Clinical suspicion is essential, especially in immunocompromised patients. In HIV-infected patients, VZV encephalitis is less frequent than tuberculosis, progressive multifocal leukoencephalopathy, cryptococcosis, or primary CNS lymphoma. In addition, its presentation is usually subacute and unspecific (headache, fever, altered consciousness, seizures, and/or focal neurologic deficits)4 and the rash is absent.5 VZV encephalitis is catastrophic despite therapy, with an estimated 33% mortality in HIV-infected patients and frequent neurologic sequelae in survivors.

VZV causes a productive infection in arteries,5 with secondary inflammation inducing vascular remodeling causing stenosis/occlusion. Hemorrhage can result from necrotizing angiitis or media disruption with aneurysm formation.6 Therefore, VZV infection must be considered in cryptogenic stroke patients or CNS vasculitis.

Brain MRI usually shows multiple ischemic lesions typically involving the gray-white matter junction.4 Angiographic features include focal stenosis, often with poststenotic dilation.4,5 CSF is normal (40% of HIV-infected patients) or shows modest pleocytosis, erythrocytes, and/or increased proteins.4 VZV DNA in CSF has 98% specificity and 80% sensitivity in HIV-infected patients,7 with a correlation between the viral load and CNS disease severity. However, VZV DNA becomes undetectable after weeks.5 CSF anti-VZV immunoglobulin G (IgG) has greater diagnostic value, increasing as VZV DNA becomes undetectable.

Optimally, CSF/serum VZV IgG index is needed to confirm intrathecal antibody production. DNA or IgG virologic confirmation in CSF is required for VZV encephalitis diagnosis, and only a negative result in both can rule out this infection. VZV in CSF is not routinely or timely tested, and VZV encephalitis diagnosis may be frequently missed.

First-line treatment for VZV encephalitis is acyclovir (10–15 mg/kg, tid, 10–14 days).2,4 In severe cases, oral/IV steroids are an option for arterial inflammation,4 but long-term steroids are not recommended.1,4 If acyclovir resistance is suspected, foscarnet is advised.1

In our patient, timely histopathologic confirmation was impossible; however, VZV DNA in CSF and sustained improvement after foscarnet and steroids support our diagnosis.

Conclusions.

VZV encephalitis has an unspecific presentation and may explain a significant proportion of cases of encephalitis classified as undetermined. Clinical suspicion is essential and routine screening for VZV in CSF needs to be implemented.

Footnotes

  • Author contributions: Inês B. Marques contributed to data acquisition and drafted the manuscript. Stuart Flanagan contributed to data acquisition and revised the draft critically for important intellectual content. Heather Noble contributed to data acquisition and revised the draft critically for important intellectual content. Gavin Giovannoni revised the draft critically for important intellectual content. Monica Marta contributed to data acquisition, participated in the manuscript design and coordination, and helped to draft the manuscript.

  • Study funding: No targeted funding reported.

  • Disclosure: I.B. Marques received research support from Tecnifar. S. Flanagan received travel funding from BHIVA/MSD, is on the advisory board for the social media editor at STI Journal, and was an on-air media doctor for BBC. H. Noble reports no disclosures. G. Giovannoni is on the scientific advisory board for Biogen-Idec, Fiveprime, Genzyme, GW Pharma, Ironwood, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex Pharmaceuticals, Abbvie, and Canbex; has received honoraria from Biogen-Idec, Genzyme, GW Pharma, Merck-Serono, Novartis, Roche, and Teva; is an editor for Multiple Sclerosis and Related Disorders; has consulted for Biogen-Idec, Fiveprime, Genzyme, GQ Pharma, Ironwood, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex Pharmaceuticals, Abbvie, and Canbex; is on the speakers' bureau for Novartis and Teva; and has received research support from Genzyme and Merck. M. Marta has received travel funding from Biogen-Idec and Abbott Laboratories and has received research support from Merck-Serono. Go to Neurology.org/nn for full disclosures. The Article Processing Charge was paid by the authors.

  • Received September 15, 2014.
  • Accepted in final form January 8, 2015.
  • © 2015 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

References

  1. 1.↵
    1. Masur H,
    2. Brooks JT,
    3. Benson CA,
    4. Holmes KK,
    5. Pau AK,
    6. Kaplan JE
    . Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:1308–1311. doi: 10.1093/cid/ciu094.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Tunkel AR,
    2. Glaser CA,
    3. Bloch KC,
    4. et al
    . The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008;47:303–327. doi: 10.1086/589747.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Granerod J,
    2. Ambrose HE,
    3. Davies NW,
    4. et al
    . Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010;10:835–844. doi: 10.1016/S1473-3099(10)70222-X.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Gilden D,
    2. Cohrs RJ,
    3. Mahalingam R,
    4. Nagel MA
    . Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol 2009;8:731–740. doi: 10.1016/S1474-4422(09)70134-6.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Nagel MA,
    2. Cohrs RJ,
    3. Mahalingam R,
    4. et al
    . The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008;70:853–860. doi: 10.1212/01.wnl.0000304747.38502.e8.
    OpenUrlCrossRef
  6. 6.↵
    1. Nagel MA,
    2. Traktinskiy I,
    3. Azarkh Y,
    4. et al
    . Varicella zoster virus vasculopathy: analysis of virus-infected arteries. Neurology 2011;77:364–370. doi: 10.1212/WNL.0b013e3182267bfa.
    OpenUrlCrossRef
  7. 7.↵
    1. Corral I,
    2. Quereda C,
    3. Antela A,
    4. et al
    . Neurological complications of varicella-zoster virus in human immunodeficiency virus-infected patients: changes in prevalence and diagnostic utility of polymerase chain reaction in cerebrospinal fluid. J Neurovirol 2003;9:129–135. doi: 10.1080/13550280390173300.
    OpenUrlPubMed
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • Encephalitis
  • Vasculitis
  • Viral infections
  • HIV

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology - Neuroimmunology Neuroinflammation: 8 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise